[Place of the sulprostone in therapeutic interruptions of the pregnancy].
BACKGROUND
Therapeutic interruption of the pregnancies of the 2nd and 3-rd quarter is often badly accepted by the patients and it is original that his realization is easy, effective and the less traumatic possible. In this indication, the sulprostone (Nalador) is a big contribution.


OBJECTIVE
The purpose of our study is to review this product, to describe our experience concerning its use in the therapeutic interruptions of pregnancies and to study alternatives in case of failure or of against indication in its use.


METHODS
It is about a forward-looking study opened from the 01-07-02 led in the service "A" of the CMNT. We brought together 30 women where a therapeutic interruption of the pregnancy was put and who did'nt present of against indications to the sulprostone.


RESULTS
The average age was of 27 years with extremes from 18 to 39 years 50% of our patients were nullipares. The terms of pregnancy varied from 16 to 28 LIMITED COMPANIES with an average of 20 LIMITED COMPANIES. The indications of these terminations of pregnancy were maternal in 33.33% of cases and foetal in 66.66% of cases. The average number of light bulbs of Nalador used by the women was of 2.25 with extremes going from 1 to 4. The delay of eviction from the beginning of the induction was on average of 21 hours, with a rate of success of 90%. We did not regret any break uterine Delivery was incomplete requiring a uterine revision under general anesthetic in 5 cases. Tolerance was good in general In case of failure alternatives were: the misoprostol (cytotec *), the Probe extra amniotic dries and the wet Probe.


CONCLUSIONS
The sulprostone by intravenous way constitutes an effective method of medical interruption of the pregnancy in the 2-nd and 3-rd quarter with a satisfactory tolerance and a rate of success of 90 %.
Centre De Maternite Et De Néonatologie De Tunis, Service A.
Bechir
B
Khemiri
Afef
A
Ben Slama
Abdelkhalek
A
Hsini
Mohamed
M
Bedis Chennoufi
Ezzedine
E
Sfar
H
H
Chelli
Mourad
M
Bouchnak
Hayene
H
Maghrebi
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects; D000032:Abortion, Therapeutic / Q000295:instrumentation; D000293:Adolescent; D000328:Adult; D000013:Congenital Abnormalities; D003967:Diarrhea / Q000139:chemically induced; D015232:Dinoprostone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005313:Fetal Death; D005865:Gestational Age; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage; D010298:Parity; D017699:Pelvic Pain / Q000209:etiology; D011247:Pregnancy; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol; C016767:sulprostone; D015232:Dinoprostone